Bioheart and PharmaCell Open GMP Lab Facility in Europe
News Jun 05, 2006
This lab is an advanced research facility that also has GMP cell production capabilities to support research related to Bioheart's adult muscle stem cell technology.
Bioheart has developed MyoCell™, a cell therapy that involves extracting and culturing cells from a patient's own thigh muscle.
These cells are inserted back into the patient's damaged heart region via the MyoCath®, a minimally-invasive injection-catheter system.
"We are excited about the opening of this GMP facility that will support our research," said Howard J. Leonhardt, Chairman and CEO of Bioheart.
"We chose the Maastricht region due to its highly educated workforce and its ideal location with close proximity to top research institutes such as the University of Maastricht," he added.
How Hematopoietic Stem Cells Balance Activation and DormancyNews
Researchers have shown how intracellular signalling can safeguard the delicate balance between hematopoietic stem cell activation and dormancy.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Myelin Encourages Neuronal Growth Following Spinal Cord InjuryNews
Scientitsts report that adult rat myelin actually stimulated axonal outgrowth in rat neural precursor cells (NPCs) and human induced pluripotent (iPSC)-derived neural stem cells (NSCs).READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018